Stock AnalizGeneDx Holdings Corp. WGS
Medical/Nursing Services · IPO 2020 · data as of November 13, 2026
GeneDx Holdings Corp. (WGS) is a healthcare company listed in the US with a market value of about $1.6B. In the twelve months to September 30, 2026 it had revenue of $461M and net income of -$111M, a net margin of -24.1%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 19% a year, a 5-year average ROIC of -75%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $461M | $428M | $305M | $203M | $235M | $212M | $179M | $196M |
| Net income | -$111M | -$21M | -$52M | -$176M | -$549M | -$245M | -$241M | -$30M |
| Free cash flow | -$101M | $14M | -$34M | -$185M | -$326M | -$200M | -$117M | -$31M |
| EPS (diluted) | $-3.78 | $-0.73 | $-1.94 | $-7.23 | $-53.63 | $-74.91 | $-1552188.00 | $-8713848.00 |
| Net margin | -24.1% | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | -134.6% | -15.1% |
| ROIC | — | -3.2% | -6.7% | -54.3% | -196.7% | -111.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $82.00, 57% above the current price; targets range from $65.00 to $102.00; the consensus rating is “Strong buy”; expected EPS is $0.38 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is GeneDx Holdings stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 94% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does GeneDx Holdings pay a dividend?
Not currently.
Is GeneDx Holdings a good stock to buy?
We do not give buy or sell advice. GeneDx Holdings scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.